Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

john_nason

Teva names new President, TAPI and Biologics Operations

September 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Novartis, Teva, appointment

Israeli generic drug specialist Teva has announced its appointment of John Nason in a multi-faceted role as President of Teva …

Appointment
d2644e613f

Novartis eyecare unit Alcon to set up new HQ in Geneva, Switzerland

September 11, 2018
Manufacturing and Production Alcon, Novartis, eye care, pharma

Alcon, the eyecare unit of Novartis, is set to move to a new home next year, after its parent company …

News

Novartis sells key Sandoz US portfolios to Aurobindo for $1bn

September 6, 2018
Sales and Marketing Aurobindo, Novartis, Sandoz, pharma

Novartis has revealed it is to sell the dermatology and generic US oral solids portfolios of its generics arm Sandoz …

News

Novartis’ CAR T therapy Kymriah to become available on the NHS

September 5, 2018
Research and Development CAR T, CAR-T, Gilead, Kymriah, NHS, Novartis

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

August 31, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Medicare, Novartis, UK, brexit, generics, king bio, pharma, top ten

Eight months of 2018 down – where has the year gone? As we move from August into September, and a …

News
novartis_mit_us

Novartis to create 450 new jobs at Aargau site after Kymriah thumbs up

August 29, 2018
Research and Development CAR T, CAR-T, Jobs, Kymriah, Novartis

Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
novartis_window

Novartis’ investigational combo impresses in breast cancer sub-group

August 23, 2018
Research and Development Cancer, Novartis, breast cancer, fulvestrant, pharma

Novartis has revealed positive new data for its investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) combined with fulvestrant in the treatment …

News

Novartis hands over global rights for two oncology drugs to Shanghai’s Laekna

August 2, 2018
Sales and Marketing Cancer, Laekna, Novartis, oncology, pharma

Novartis has revealed that it has jettisoned two of its clinical stage oncology products along with exclusive global development and …

News
novartis_outside_1

Novartis migraine prevention drug scores EU approval

July 31, 2018
Manufacturing and Production, Sales and Marketing Aimovig, Europe, Novartis, migraine, pharma

Novartis is celebrating the news that its calcitonin gene-related peptide receptor (CGRP-R) pathway therapy Aimovig (erenumab) has been approved by …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 20, 2018
Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10

As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …

News
merckwindow_web

Merck joins Pizer and Novartis in reducing drug prices

July 20, 2018
Medical Communications Merck, Novartis, Pfizer, Trump, Twitter, price hikes

Merck & Co. have joined Pfizer and Novartis in halting price increases on medicines in the United States. The American …

News
donald_trump_29496131773

Donald Trump thanks Novartis for halting price hikes

July 20, 2018
Medical Communications Novartis, Pfizer, Trump, Twitter, price hikes

Donald Trump has thanked Swiss multinational Novartis for halting price hikes on prescription drugs in the United States. The US …

News

Novartis buys eczema drug in €95m deal

July 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, deal, eczema, experimental, patent

Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and …

News
shutterstock_138095450

Novartis follows Pfizer’s lead, pledges no price hikes in 2018

July 18, 2018
Research and Development, Sales and Marketing Novartis, Pfizer, President trump, Trump, US, pharma

Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026